Actinium Pharmaceuticals, Inc. (Actinium) is a clinical-stage biopharmaceutical company engaged in developing cancer treatments. The Company is engaged in developing therapies for diseases using its alpha particle immunotherapy platform and other related technologies. The Company's products include Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), and Iomab-B, an antibody-drug construct containing iodine 131 (I-131). Actimab-A is in human clinical trials stage for acute myeloid leukemia (AML) and Iomab-B in clinical trial stage for use in myeloconditioning for hematopoietic stem cells transplantation (HSCT) in various indications. Its products under development are monoclonal antibodies labeled with radioisotopes. It has four product candidates in clinical trials: Actimab-A (HuM195-Ac-225), Iomab-B (BC8-I-131), BC8-Y-90 and BC8-SA. It is pursuing development of Actimab-A and Iomab-B, while BC8-Y-90 and BC8-SA are in physician sponsored clinical phase I trials.
Number of employees : 32 people.
|Vote ||Quantity||Free-Float||Company-owned shares||Total Float
|The Vanguard Group, Inc. ||808,015||
|District 2 Capital LP ||357,467||
|Rubric Capital Management LP ||294,683||
|Michael Bigger ||292,729||
|Armistice Capital LLC ||203,331||
|Sio Capital Management LLC ||189,062||
|J. Goldman & Co. LP ||168,749||
|BlackRock Fund Advisors ||162,299||
|Geode Capital Management LLC ||152,678||
|Anson Funds Management LP ||137,128||
|Company contact information|
Sector Bio Therapeutic Drugs
Connections : Actinium Pharmaceuticals, Inc.